The Therapeutic Nuclear Medicines market revenue was xx.xx Million USD in 2019, and will reach xx.xx Million USD in 2025, with a CAGR of x.x% during 2020-2025.
Under COVID-19 outbreak globally, this report provides 360 degrees of analysis from supply chain, import and export control to regional government policy and future influence on the industry. Detailed analysis about market status (2015-2020), enterprise competition pattern, advantages and disadvantages of enterprise products, industry development trends (2020-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to end users of this industry are analyzed scientifically, the trends of product circulation and sales channel will be presented as well. Considering COVID-19, this report provides comprehensive and in-depth analysis on how the epidemic push this industry transformation and reform.
In COVID-19 outbreak, Chapter 2.2 of this report provides an analysis of the impact of COVID-19 on the global economy and the Therapeutic Nuclear Medicines industry.
Chapter 3.7 covers the analysis of the impact of COVID-19 from the perspective of the industry chain.
In addition, chapters 7-11 consider the impact of COVID-19 on the regional economy.
The Therapeutic Nuclear Medicines market can be split based on product types, major applications, and important countries as follows:
Key players in the global Therapeutic Nuclear Medicines market covered in Chapter 12:
Mallinckrodt plc.
Cardinal Health Inc.
Advanced Accelerator Applications S.A.
Eczacibasi-Monrol Nuclear Products
GE Healthcare
Bracco Imaging S.p.A
Nordion, Inc.
IBA Molecular Imaging
Bayer AG
Lantheus Medical Imaging Inc.
In Chapter 4 and 14.1, on the basis of types, the Therapeutic Nuclear Medicines market from 2015 to 2025 is primarily split into:
Beta Emitters
Alpha Emitters
Brachytherapy Products
In Chapter 5 and 14.2, on the basis of applications, the Therapeutic Nuclear Medicines market from 2015 to 2025 covers:
Hospitals
Ambulatory Surgical Centers
Radiology Clinics
Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2025) of the following regions are covered in Chapter 6, 7, 8, 9, 10, 11, 14:
North America (Covered in Chapter 7 and 14)
United States
Canada
Mexico
Europe (Covered in Chapter 8 and 14)
Germany
UK
France
Italy
Spain
Russia
Others
Asia-Pacific (Covered in Chapter 9 and 14)
China
Japan
South Korea
Australia
India
Southeast Asia
Others
Middle East and Africa (Covered in Chapter 10 and 14)
Saudi Arabia
UAE
Egypt
Nigeria
South Africa
Others
South America (Covered in Chapter 11 and 14)
Brazil
Argentina
Columbia
Chile
Others
Years considered for this report:
Historical Years: 2015-2019
Base Year: 2019
Estimated Year: 2020
Forecast Period: 2020-2025
Table of Content
1 Therapeutic Nuclear Medicines Introduction and Market Overview
1.1 Objectives of the Study
1.2 Overview of Therapeutic Nuclear Medicines
1.3 Scope of The Study
1.3.1 Key Market Segments
1.3.2 Players Covered
1.3.3 COVID-19's impact on the Therapeutic Nuclear Medicines industry
1.4 Methodology of The Study
1.5 Research Data Source
2 Executive Summary
2.1 Market Overview
2.1.1 Global Therapeutic Nuclear Medicines Market Size, 2015 - 2020
2.1.2 Global Therapeutic Nuclear Medicines Market Size by Type, 2015 - 2020
2.1.3 Global Therapeutic Nuclear Medicines Market Size by Application, 2015 - 2020
2.1.4 Global Therapeutic Nuclear Medicines Market Size by Region, 2015 - 2025
2.2 Business Environment Analysis
2.2.1 Global COVID-19 Status and Economic Overview
2.2.2 Influence of COVID-19 Outbreak on Therapeutic Nuclear Medicines Industry Development
3 Industry Chain Analysis
3.1 Upstream Raw Material Suppliers of Therapeutic Nuclear Medicines Analysis
3.2 Major Players of Therapeutic Nuclear Medicines
3.3 Therapeutic Nuclear Medicines Manufacturing Cost Structure Analysis
3.3.1 Production Process Analysis
3.3.2 Manufacturing Cost Structure of Therapeutic Nuclear Medicines
3.3.3 Labor Cost of Therapeutic Nuclear Medicines
3.4 Market Distributors of Therapeutic Nuclear Medicines
3.5 Major Downstream Buyers of Therapeutic Nuclear Medicines Analysis
3.6 The Impact of Covid-19 From the Perspective of Industry Chain
3.7 Regional Import and Export Controls Will Exist for a Long Time
3.8 Continued downward PMI Spreads Globally
4 Global Therapeutic Nuclear Medicines Market, by Type
4.1 Global Therapeutic Nuclear Medicines Value and Market Share by Type (2015-2020)
4.2 Global Therapeutic Nuclear Medicines Production and Market Share by Type (2015-2020)
4.3 Global Therapeutic Nuclear Medicines Value and Growth Rate by Type (2015-2020)
4.3.1 Global Therapeutic Nuclear Medicines Value and Growth Rate of Beta Emitters
4.3.2 Global Therapeutic Nuclear Medicines Value and Growth Rate of Alpha Emitters
4.3.3 Global Therapeutic Nuclear Medicines Value and Growth Rate of Brachytherapy Products
4.4 Global Therapeutic Nuclear Medicines Price Analysis by Type (2015-2020)
5 Therapeutic Nuclear Medicines Market, by Application
5.1 Downstream Market Overview
5.2 Global Therapeutic Nuclear Medicines Consumption and Market Share by Application (2015-2020)
5.3 Global Therapeutic Nuclear Medicines Consumption and Growth Rate by Application (2015-2020)
5.3.1 Global Therapeutic Nuclear Medicines Consumption and Growth Rate of Hospitals (2015-2020)
5.3.2 Global Therapeutic Nuclear Medicines Consumption and Growth Rate of Ambulatory Surgical Centers (2015-2020)
5.3.3 Global Therapeutic Nuclear Medicines Consumption and Growth Rate of Radiology Clinics (2015-2020)
6 Global Therapeutic Nuclear Medicines Market Analysis by Regions
6.1 Global Therapeutic Nuclear Medicines Sales, Revenue and Market Share by Regions
6.1.1 Global Therapeutic Nuclear Medicines Sales by Regions (2015-2020)
6.1.2 Global Therapeutic Nuclear Medicines Revenue by Regions (2015-2020)
6.2 North America Therapeutic Nuclear Medicines Sales and Growth Rate (2015-2020)
6.3 Europe Therapeutic Nuclear Medicines Sales and Growth Rate (2015-2020)
6.4 Asia-Pacific Therapeutic Nuclear Medicines Sales and Growth Rate (2015-2020)
6.5 Middle East and Africa Therapeutic Nuclear Medicines Sales and Growth Rate (2015-2020)
6.6 South America Therapeutic Nuclear Medicines Sales and Growth Rate (2015-2020)
7 North America Therapeutic Nuclear Medicines Market Analysis by Countries
7.1 The Influence of COVID-19 on North America Market
7.2 North America Therapeutic Nuclear Medicines Sales, Revenue and Market Share by Countries
7.2.1 North America Therapeutic Nuclear Medicines Sales by Countries (2015-2020)
7.2.2 North America Therapeutic Nuclear Medicines Revenue by Countries (2015-2020)
7.3 United States Therapeutic Nuclear Medicines Sales and Growth Rate (2015-2020)
7.4 Canada Therapeutic Nuclear Medicines Sales and Growth Rate (2015-2020)
7.5 Mexico Therapeutic Nuclear Medicines Sales and Growth Rate (2015-2020)
8 Europe Therapeutic Nuclear Medicines Market Analysis by Countries
8.1 The Influence of COVID-19 on Europe Market
8.2 Europe Therapeutic Nuclear Medicines Sales, Revenue and Market Share by Countries
8.2.1 Europe Therapeutic Nuclear Medicines Sales by Countries (2015-2020)
8.2.2 Europe Therapeutic Nuclear Medicines Revenue by Countries (2015-2020)
8.3 Germany Therapeutic Nuclear Medicines Sales and Growth Rate (2015-2020)
8.4 UK Therapeutic Nuclear Medicines Sales and Growth Rate (2015-2020)
8.5 France Therapeutic Nuclear Medicines Sales and Growth Rate (2015-2020)
8.6 Italy Therapeutic Nuclear Medicines Sales and Growth Rate (2015-2020)
8.7 Spain Therapeutic Nuclear Medicines Sales and Growth Rate (2015-2020)
8.8 Russia Therapeutic Nuclear Medicines Sales and Growth Rate (2015-2020)
9 Asia Pacific Therapeutic Nuclear Medicines Market Analysis by Countries
9.1 The Influence of COVID-19 on Asia Pacific Market
9.2 Asia Pacific Therapeutic Nuclear Medicines Sales, Revenue and Market Share by Countries
9.2.1 Asia Pacific Therapeutic Nuclear Medicines Sales by Countries (2015-2020)
9.2.2 Asia Pacific Therapeutic Nuclear Medicines Revenue by Countries (2015-2020)
9.3 China Therapeutic Nuclear Medicines Sales and Growth Rate (2015-2020)
9.4 Japan Therapeutic Nuclear Medicines Sales and Growth Rate (2015-2020)
9.5 South Korea Therapeutic Nuclear Medicines Sales and Growth Rate (2015-2020)
9.6 India Therapeutic Nuclear Medicines Sales and Growth Rate (2015-2020)
9.7 Southeast Asia Therapeutic Nuclear Medicines Sales and Growth Rate (2015-2020)
9.8 Australia Therapeutic Nuclear Medicines Sales and Growth Rate (2015-2020)
10 Middle East and Africa Therapeutic Nuclear Medicines Market Analysis by Countries
10.1 The Influence of COVID-19 on Middle East and Africa Market
10.2 Middle East and Africa Therapeutic Nuclear Medicines Sales, Revenue and Market Share by Countries
10.2.1 Middle East and Africa Therapeutic Nuclear Medicines Sales by Countries (2015-2020)
10.2.2 Middle East and Africa Therapeutic Nuclear Medicines Revenue by Countries (2015-2020)
10.3 Saudi Arabia Therapeutic Nuclear Medicines Sales and Growth Rate (2015-2020)
10.4 UAE Therapeutic Nuclear Medicines Sales and Growth Rate (2015-2020)
10.5 Egypt Therapeutic Nuclear Medicines Sales and Growth Rate (2015-2020)
10.6 Nigeria Therapeutic Nuclear Medicines Sales and Growth Rate (2015-2020)
10.7 South Africa Therapeutic Nuclear Medicines Sales and Growth Rate (2015-2020)
11 South America Therapeutic Nuclear Medicines Market Analysis by Countries
11.1 The Influence of COVID-19 on Middle East and Africa Market
11.2 South America Therapeutic Nuclear Medicines Sales, Revenue and Market Share by Countries
11.2.1 South America Therapeutic Nuclear Medicines Sales by Countries (2015-2020)
11.2.2 South America Therapeutic Nuclear Medicines Revenue by Countries (2015-2020)
11.3 Brazil Therapeutic Nuclear Medicines Sales and Growth Rate (2015-2020)
11.4 Argentina Therapeutic Nuclear Medicines Sales and Growth Rate (2015-2020)
11.5 Columbia Therapeutic Nuclear Medicines Sales and Growth Rate (2015-2020)
11.6 Chile Therapeutic Nuclear Medicines Sales and Growth Rate (2015-2020)
12 Competitive Landscape
12.1 Mallinckrodt plc.
12.1.1 Mallinckrodt plc. Basic Information
12.1.2 Therapeutic Nuclear Medicines Product Introduction
12.1.3 Mallinckrodt plc. Production, Value, Price, Gross Margin 2015-2020
12.2 Cardinal Health Inc.
12.2.1 Cardinal Health Inc. Basic Information
12.2.2 Therapeutic Nuclear Medicines Product Introduction
12.2.3 Cardinal Health Inc. Production, Value, Price, Gross Margin 2015-2020
12.3 Advanced Accelerator Applications S.A.
12.3.1 Advanced Accelerator Applications S.A. Basic Information
12.3.2 Therapeutic Nuclear Medicines Product Introduction
12.3.3 Advanced Accelerator Applications S.A. Production, Value, Price, Gross Margin 2015-2020
12.4 Eczacibasi-Monrol Nuclear Products
12.4.1 Eczacibasi-Monrol Nuclear Products Basic Information
12.4.2 Therapeutic Nuclear Medicines Product Introduction
12.4.3 Eczacibasi-Monrol Nuclear Products Production, Value, Price, Gross Margin 2015-2020
12.5 GE Healthcare
12.5.1 GE Healthcare Basic Information
12.5.2 Therapeutic Nuclear Medicines Product Introduction
12.5.3 GE Healthcare Production, Value, Price, Gross Margin 2015-2020
12.6 Bracco Imaging S.p.A
12.6.1 Bracco Imaging S.p.A Basic Information
12.6.2 Therapeutic Nuclear Medicines Product Introduction
12.6.3 Bracco Imaging S.p.A Production, Value, Price, Gross Margin 2015-2020
12.7 Nordion, Inc.
12.7.1 Nordion, Inc. Basic Information
12.7.2 Therapeutic Nuclear Medicines Product Introduction
12.7.3 Nordion, Inc. Production, Value, Price, Gross Margin 2015-2020
12.8 IBA Molecular Imaging
12.8.1 IBA Molecular Imaging Basic Information
12.8.2 Therapeutic Nuclear Medicines Product Introduction
12.8.3 IBA Molecular Imaging Production, Value, Price, Gross Margin 2015-2020
12.9 Bayer AG
12.9.1 Bayer AG Basic Information
12.9.2 Therapeutic Nuclear Medicines Product Introduction
12.9.3 Bayer AG Production, Value, Price, Gross Margin 2015-2020
12.10 Lantheus Medical Imaging Inc.
12.10.1 Lantheus Medical Imaging Inc. Basic Information
12.10.2 Therapeutic Nuclear Medicines Product Introduction
12.10.3 Lantheus Medical Imaging Inc. Production, Value, Price, Gross Margin 2015-2020
13 Industry Outlook
13.1 Market Driver Analysis
13.1.2 Market Restraints Analysis
13.1.3 Market Trends Analysis
13.2 Merger, Acquisition and New Investment
13.3 News of Product Release
14 Global Therapeutic Nuclear Medicines Market Forecast
14.1 Global Therapeutic Nuclear Medicines Market Value & Volume Forecast, by Type (2020-2025)
14.1.1 Beta Emitters Market Value and Volume Forecast (2020-2025)
14.1.2 Alpha Emitters Market Value and Volume Forecast (2020-2025)
14.1.3 Brachytherapy Products Market Value and Volume Forecast (2020-2025)
14.2 Global Therapeutic Nuclear Medicines Market Value & Volume Forecast, by Application (2020-2025)
14.2.1 Hospitals Market Value and Volume Forecast (2020-2025)
14.2.2 Ambulatory Surgical Centers Market Value and Volume Forecast (2020-2025)
14.2.3 Radiology Clinics Market Value and Volume Forecast (2020-2025)
14.3 Therapeutic Nuclear Medicines Market Analysis and Forecast by Region
14.3.1 North America Market Value and Consumption Forecast (2020-2025)
14.3.2 Europe Market Value and Consumption Forecast (2020-2025)
14.3.3 Asia Pacific Market Value and Consumption Forecast (2020-2025)
14.3.4 Middle East and Africa Market Value and Consumption Forecast (2020-2025)
14.3.5 South America Market Value and Consumption Forecast (2020-2025)
15 New Project Feasibility Analysis
15.1 Industry Barriers and New Entrants SWOT Analysis
15.1.1 Porter